Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib Vaccine (GSK217744)
Condition(s):Acellular Pertussis; Hepatitis B; Haemophilus Influenzae Type b; Tetanus; Diphtheria; PoliomyelitisLast Updated:July 17, 2020Completed